Key result
SGLT2 inhibitors showed modest benefits for cardiovascular mortality in diabetes (Meta-NNT 118) but substantial benefits for heart failure hospitalization in heart failure populations (Meta-NNT 25).
Why the study?
Absolute treatment effects (numbers needed to treat) of novel antidiabetic drugs for cardiovascular outcomes had not been comprehensively evaluated.
Do novel antidiabetic drugs (DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors) reduce cardiovascular mortality and hospitalization for heart failure in patients with diabetes or heart failure?
Meta-Analysis (n=96,860)
Do novel antidiabetic drugs (DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors) reduce cardiovascular mortality and hospitalization for heart failure in patients with diabetes or heart failure?
SGLT2 inhibitors and GLP-1 receptor agonists offer modest absolute benefits for cardiovascular mortality and heart failure hospitalization in primary type 2 diabetes, but SGLT2 inhibitors provide substantial benefits for heart failure hospitalization in primary heart failure populations (NNT 25).
Answers are grounded in this paper and cite their sources.
Provides NNTs for novel antidiabetics on CM/HHF; extends prior relative-risk data to inform absolute-benefit discussions in practice.
AIMS: Absolute treatment effects-i.e. numbers needed to treat (NNTs)-of novel antidiabetic drugs for cardiovascular outcomes have not been comprehensively evaluated. We aimed to perform a meta-analysis of digitalized individual patient outcomes to display and compare absolute treatment effects. METHODS AND RESULTS: Individual patient time-to-event information from Kaplan-Meier plots of cardiovascular mortality (CM) and/or hospitalization for heart failure (HHF) endpoints from cardiovascular outcome trials (CVOTs) evaluating dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and sodium glucose transporter 2 (SGLT2) inhibitors vs. placebo were digitalized using WebPlotDigitizer 4.2 and the R code of Guyot et al.; Weibull regression models were generated, validated, and used to estimate NNT for individual trials; random-effects meta-analysis generated Meta-NNT with 95% confidence intervals. Sixteen CVOTs reported time-to-event information (14 in primary diabetes and 2 in primary heart failure populations). Thirteen studies including 96 860 patients were meta-analysed for CM: At the median follow-up of 30 months, Meta-NNTs were 178 (64 to ∞ to -223) for DPP-4 inhibitors, 261 (158 to 745) for GLP-1 receptor agonists, and 118 (68 to 435) for SGLT2 inhibitors. Ten studies including 96 128 patients were meta-analysed for HHF: At the median follow-up of 29 months, estimated Meta-NNTs were -644 (229 to ∞ to -134) for DPP-4 inhibitors, 441 (184 to ∞ to -1100) for GLP-1 receptor agonists, and 126 (91 to 208) for SGLT2 inhibitors. SGLT2 inhibitors were especially effective for HHF in primary heart failure populations [Meta-NNT 25 (19 to 39)] vs. primary diabetes populations [Meta-NNT 233 (167 to 385)] at 16 months of follow-up. CONCLUSIONS: We found only modest treatment benefits of GLP-1 receptor agonists and SGLT2 inhibitors for CM and HHF in primary type 2 diabetes mellitus populations. In primary heart failure populations, SGLT2 inhibitor benefits were substantial and comparable in efficacy to established heart failure medication.
No takes yet. Share an insight, caveat, or question.
Wolff et al. (2022) conducted a meta-analysis in Type 2 diabetes mellitus and heart failure (n=96,860). Novel antidiabetic drugs (DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors) vs. Placebo was evaluated on Cardiovascular mortality (Meta-NNT 118, 95% CI 68 to 435). SGLT2 inhibitors showed modest benefits for cardiovascular mortality in diabetes (Meta-NNT 118) but substantial benefits for heart failure hospitalization in heart failure populations (Meta-NNT 25).
Synapse has enriched 10 related papers. Consider them for comparative context: